| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780648 | Gynecologic Oncology | 2018 | 6 Pages |
Abstract
This study provided a promising rationale for the clinical investigation of tyrosine kinase inhibitors for the treatment of cervical cancer with ERBB2 mutations. Patients with non-squamous cell carcinomas have priority as candidates for ERBB2-targeted therapy. Concurrent PIK3CA/RAS mutations should be considered in the design of clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Libing Xiang, Wei Jiang, Shuang Ye, Tiancong He, Xuan Pei, Jiajia Li, David Wai Chan, Hextan Yuen Sheung Ngan, Fang Li, Pingping Tao, Xuxia Shen, Xiaoyan Zhou, Xiaohua Wu, Gong Yang, Huijuan Yang,